Our top pick for
Exponent, Inc is a consulting services business based in the US. Exponent shares (EXPO) are listed on the NASDAQ and all prices are listed in US Dollars. Exponent employs 1,168 staff and has a trailing 12-month revenue of around USD$378.4 million.
|52-week range||USD$57.6106 - USD$100.94|
|50-day moving average||USD$92.7665|
|200-day moving average||USD$83.0826|
|Wall St. target price||USD$104|
|Dividend yield||USD$0.76 (0.79%)|
|Earnings per share (TTM)||USD$1.55|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Exponent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exponent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Exponent's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 63x. In other words, Exponent shares trade at around 63x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Exponent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.14. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exponent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Exponent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$90.1 million.
The EBITDA is a measure of a Exponent's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$378.4 million|
|Operating margin TTM||22%|
|Gross profit TTM||USD$128.4 million|
|Return on assets TTM||9.1%|
|Return on equity TTM||23.2%|
|Market capitalisation||USD$5 billion|
TTM: trailing 12 months
There are currently 669,985 Exponent shares held short by investors – that's known as Exponent's "short interest". This figure is 8.6% up from 616,764 last month.
There are a few different ways that this level of interest in shorting Exponent shares can be evaluated.
Exponent's "short interest ratio" (SIR) is the quantity of Exponent shares currently shorted divided by the average quantity of Exponent shares traded daily (recently around 235082.45614035). Exponent's SIR currently stands at 2.85. In other words for every 100,000 Exponent shares traded daily on the market, roughly 2850 shares are currently held short.
However Exponent's short interest can also be evaluated against the total number of Exponent shares, or, against the total number of tradable Exponent shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exponent's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Exponent shares in existence, roughly 10 shares are currently held short) or 0.0177% of the tradable shares (for every 100,000 tradable Exponent shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Exponent.
Find out more about how you can short Exponent stock.
Dividend payout ratio: 55% of net profits
Recently Exponent has paid out, on average, around 55% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.82% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Exponent shareholders could enjoy a 0.82% return on their shares, in the form of dividend payments. In Exponent's case, that would currently equate to about $0.76 per share.
Exponent's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Exponent's most recent dividend payout was on 26 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 March 2021 (the "ex-dividend date").
Exponent's shares were split on a 2:1 basis on 8 June 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Exponent shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Exponent shares which in turn could have impacted Exponent's share price.
Over the last 12 months, Exponent's shares have ranged in value from as little as $57.6106 up to $100.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exponent's is 0.3431. This would suggest that Exponent's shares are less volatile than average (for this exchange).
Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific segment provides services in the areas of biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, thermal sciences, and vehicle engineering. The Environmental and Health segment offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. The company offers approximately 90 different technical disciplines to solve complicated issues facing industry and government. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors of the economy. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. Exponent, Inc. was founded in 1967 and is headquartered in Menlo Park, California.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.